Get the Stockscreener App
0.0051
0.00%
0.00
Nkgen Biotech Inc stock is traded at $0.0051, with a volume of 200.
It is up +0.00% in the last 24 hours and down -91.50% over the past month.
See More
Previous Close:
$0.0051
Open:
$0.0051
24h Volume:
200
Relative Volume:
0.02
Market Cap:
$N/A
Revenue:
$3,000
Net Income/Loss:
$-23.55M
P/E Ratio:
-0.00419
EPS:
-1.2183
Net Cash Flow:
$-19.75M
1W Performance:
+0.00%
1M Performance:
-91.50%
6M Performance:
-91.50%
1Y Performance:
-98.33%
1-Day Range:
$0.0051
$0.0051
1-Week Range:
$0.0051
$0.0051
52-Week Range:
$0.0003
$0.16
Nkgen Biotech Inc Stock (NKGN) Company Profile
Compare NKGN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKGN
Nkgen Biotech Inc
|
0.0051 | 0 | 3,000 | -23.55M | -19.75M | -1.2183 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nkgen Biotech Inc Stock (NKGN) Latest News
NKGen Biotech Inc. Revenue Breakdown – OTC:NKGN - TradingView
Price to earnings forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Price to sales forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Price to book forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech Amends Term Loan and Collateral Agreement - TipRanks
NKGen Biotech (NKGN) alters collateral on $5M credit facility - Stock Titan
Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to book forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to earnings forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Number of employees of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to sales forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
NKGen Biotech takes Alzheimer’s research global - Longevity.Technology
Price to earnings forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
Enterprise value to revenue forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKGen Biotech to present Alzheimer’s drug trocu... - Pluang
NKGen's CEO to Present Alzheimer’s Cell Therapy at Seoul Forum - Stock Titan
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum - GlobeNewswire
Alzheimer’s Disease Pipeline Accelerates as 200+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
NKGen Biotech Expands Convertible Financing Through New Agreement - The Globe and Mail
NKGen Biotech (NKGN) takes $2.42M note, lifts consideration shares - Stock Titan
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - PR Newswire
NKGen Biotech Expands Financing Through New Convertible Loan - TipRanks
NKGen Biotech (NKGN) expands AlpineBrook convertible deal with $412.5K note and new warrant - Stock Titan
Nkgen Biotech expands clinical trial site network for Alzheimer’s disease program across US - marketscreener.com
Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US - TradingView
NKGen Biotech Inc. is expanding its Alzheimer’s disease clinical trial site network nationwide across the United States. - Bitget
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment - marketscreener.com
New Alzheimer’s trial sites move NK cell therapy closer to East Coast patients - Stock Titan
NKGen Biotech Expands Clinical Trial Site Network for - GlobeNewswire
Number of shareholders of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech Secures Additional Convertible Financing and Warrants - TipRanks
NKGen Biotech (NKGN) expands dilutive note deal with 12M+ shares, warrant - Stock Titan
NKGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NKGen Biotech Announces Major Convertible Financing and Governance Shift - TipRanks
NKGen Biotech (NKGN) inks $39,922,134.22 secured convertible loan and control rights - Stock Titan
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - marketscreener.com
NKGen Biotech to Present Troculeucel Mechanism Data in - GlobeNewswire
NKGen Biotech to present new data on troculeuce... - Pluang
Former Bio Firm Executive Charged for Insider Trading on Drug Approval Tip - Seoul Economic Daily
NKGen reports cognitive stability in moderate Alzheimer’s trial By Investing.com - Investing.com Australia
NKGen reports cognitive stability in moderate Alzheimer’s trial - Investing.com
As of January 31, 2026, the latest financial data disclosed by Western Asset Municipal High Income Fund Inc shows that its total net asset value has reached 154.63 millions USD. - Bitget
NKGen Biotech Inc. (hereinafter referred to as NKGen Biotech) announced the integrated Phase 1 clinical trial data for its candidate therapy Troculeucel at the Ad/Pd 2026™ conference. - Bitget
NKGen Biotech Reports Combined Phase 1 Troculeucel Data - GlobeNewswire
NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer’s Disease at AD/PD 2026™ - Yahoo Finance
Troculeucel Linked to Plasma GFAP Changes and Cognitive Measures in Early Alzheimer Disease Studies - NeurologyLive
NKGen Biotech Korea Co., Ltd.: Dividend historical data and projections - marketscreener.com
Troculeucel may boost cognition, new Alzheimer’s data shows - Longevity.Technology
Nkgen Biotech Inc Stock (NKGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
3.22%
Cap:
|
Volume (24h):